

Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer

David Jacobson^{1,2}, Kathleen Moore³, Camille Gunderson³, Michelle Rowland^{3,4}, Rita Austin^{1,2}, Tanvi Prasad Honap^{1,2}, Jiawu Xu^{5,6}, Christina Warinner⁷, Krithivasan Sankaranarayanan^{2,8} and Cecil M. Lewis Jr^{1,2}

¹ Department of Anthropology, University of Oklahoma, Norman, Oklahoma, United States

² Laboratories of Molecular Anthropology and Microbiome Research (LMAMR), University of Oklahoma, Norman, Oklahoma, United States

³ Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

⁴ Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States

⁵ Ragon Institute, MGH, MIT, and Harvard, Cambridge, Massachusetts, United States

⁶ Harvard Medical School, Harvard University, Boston, Massachusetts, United States

⁷ Department of Anthropology, Harvard University, Cambridge, Massachusetts, United States

⁸ Department of Microbiology and Plant Biology, University of Oklahoma, Norman, Oklahoma, United States

ABSTRACT

Many studies investigating the human microbiome-cancer interface have focused on the gut microbiome and gastrointestinal cancers. Outside of human papillomavirus driving cervical cancer, little is known about the relationship between the vaginal microbiome and other gynecological cancers, such as ovarian cancer. In this retrospective study, we investigated the relationship between ovarian cancer, platinum-free interval (PFI) length, and vaginal and gut microbiomes. We observed that *Lactobacillus*-dominated vaginal communities were less common in women with ovarian cancer, as compared to existing datasets of similarly aged women without cancer. Primary platinum-resistance (PPR) disease is strongly associated with survivability under one year, and we found over one-third of patients with PPR (PFI < 6 months, $n = 17$) to have a vaginal microbiome dominated by *Escherichia* (>20% relative abundance), while only one platinum super-sensitive (PFI > 24 months, $n = 23$) patient had an *Escherichia*-dominated microbiome. Additionally, *L. iners* was associated with little, or no, gross residual disease, while other *Lactobacillus* species were dominant in women with >1 cm gross residual disease. In the gut microbiome, we found patients with PPR disease to have lower phylogenetic diversity than platinum-sensitive patients. The trends we observe in women with ovarian cancer and PPR disease, such as the absence of *Lactobacillus* and presence of *Escherichia* in the vaginal microbiome as well as low gut microbiome phylogenetic diversity have all been linked to other diseases and/or pro-inflammatory states, including bacterial vaginosis and autoimmune disorders. Future prospective studies are necessary to explore the translational potential and underlying mechanisms driving these associations.

Submitted 18 September 2020

Accepted 18 May 2021

Published 17 June 2021

Corresponding authors

Kathleen Moore,

Kathleen-Moore@ouhsc.edu

Cecil M. Lewis Jr, cmlewis@ou.edu

Academic editor

Elliot Lefkowitz

Additional Information and
Declarations can be found on
page 16

DOI 10.7717/peerj.11574

© Copyright

2021 Jacobson et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Genetics, Microbiology, Molecular Biology, Gynecology and Obstetrics, Women's Health
Keywords Lactobacillus, Escherichia, 16S rRNA, Platinum-based chemotherapy

INTRODUCTION

Ovarian cancer is the most deadly gynecological cancer (*Siegel, Miller & Jemal, 2019*); it kills approximately 14,000 women in the United States annually, accounting for 4.9% of all cancer-related deaths in females in the United States. In the majority of cases (>80%), ovarian cancer is not detected until stage III or later, primarily due to the nonspecific nature of ovarian cancer symptoms and lack of informative biomarkers (*Torre et al., 2018; Jacobs & Menon, 2004*). Early-stage (I or II) detection results in substantially greater 5-year survivability compared to late-stage diagnosis (III or IV): 70% versus 36% survival rate, respectively (*Baldwin et al., 2012*), highlighting the importance of discovering early-disease biomarkers.

The standard course of primary treatment in ovarian cancer is cytoreductive surgery (CRS) in combination with platinum-based chemotherapy (*Raja, Chopra & Ledermann, 2012*), which causes cytotoxicity through the formation of intra- and inter- strand adducts on DNA in cancer cells (*Dasari & Tchounwou, 2014*). The diameter of the remaining tumor after CRS, referred to as gross residual disease, is an important predictor of patient outcome, as individuals with no residual disease or residual disease <1 cm have improved survivability compared to those with tumors >1 cm after CRS (*Chang et al., 2013*). The combination of CRS and platinum-based chemotherapy is highly effective with approximately 80% of all patients showing no evidence of disease at the conclusion of initial therapy; however, recurrences occur in 70–80% of advanced stage patients and 20–25% of early-stage patients (*Ushijima, 2010*). Primary platinum resistance (recurrence of cancerous growth within six months of primary treatment cessation) develops in about 20% of patients, and is highly problematic because it is associated with a survivability of under one year and fewer effective treatment options (*Davis, Tinker & Friedlander, 2014*). Other patients may remain free of cancerous growth for more than two years, but the risk of recurrence and eventual development of treatment-resistant cancer is still unacceptably high (*Bookman, 1999; Gore et al., 1990; Markman et al., 1991; Pfisterer & Ledermann, 2006*). This merits a focus on discovering biomarkers of ovarian cancer and drivers of platinum-resistance to facilitate early cancer detection as well as better understand variation in treatment outcomes.

Recent evidence suggests that the human microbiome is an important factor in tumorigenesis, carcinogenesis, and effectiveness of chemotherapy (*Bossuet-Greif et al., 2018; Iida et al., 2013; Perez-Chanona & Trinchieri, 2016; Schwabe & Jobin, 2013*). Gut microbiome dysbiosis can influence colorectal carcinogenesis via production of genotoxic metabolites, such as colibactin, and through the promotion of a pro-inflammatory state, which contributes to cancer cell proliferation, angiogenesis, and metastasis (*Bossuet-Greif et al., 2018; Schwabe & Jobin, 2013; Crusz & Balkwill, 2015; Zackular et al., 2013; Zackular et al., 2014*). While most studies on the microbiome-cancer relationship have focused on the gut microbiome, there is growing evidence in support of the relationship between the vaginal microbiome and gynecological cancers. For example,

human papillomavirus (HPV) is a known causative agent of cervical cancer (*Champer et al., 2018; Chase et al., 2015; Muls et al., 2017*), while pelvic inflammatory disease, which is associated with shifts in vaginal microbiome composition (*Sharma et al., 2014*), has been linked to ovarian cancer development (*Lin et al., 2011*). Yet, there are still many unknowns about the relationship between the vaginal microbiome and gynecological cancers (*Champer et al., 2018; Chase et al., 2015; Muls et al., 2017; Xu et al., 2020*). Likewise, links between the vaginal microbiome and platinum-sensitivity remain elusive; however, a previous study demonstrated that cancerous growths in mice with antibiotic-depleted gut microbiomes were less susceptible to platinum-chemotherapies compared to those with high gut microbiome diversity (*Iida et al., 2013*). The microbiome has a strong, bi-directional relationship with the host immune system (*Shi et al., 2017; Thaiss et al., 2016*) and immune cells in the mice with a depleted gut microbiome produced fewer reactive oxygen species (ROS) than control mice (*Iida et al., 2013*). Decreased ROS production and platinum-resistance in mice with low gut microbiome diversity suggests a role for the microbiome in response to platinum-chemotherapy because ROS play a part in cell apoptosis after exposure to platinum chemotherapeutic agents (*Ozben, 2007*).

In this study, we assessed how the vaginal and gut microbiomes vary in ovarian cancer patients with different platinum-sensitivities, with the aim of determining whether the human microbiome can be used as a biomarker of platinum-sensitivity.

MATERIALS & METHODS

Study population

Patients, who carried a diagnosis of advanced (Stage III/IV) epithelial ovarian cancer and who were classified as primary platinum-resistant (platinum-free interval (PFI) from completion of primary platinum-based chemotherapy <6 months) or platinum super-sensitive (PFI > 24 months) and were being treated at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, were approached to participate in this study. Patients were approached when they either developed primary platinum-resistant disease or when they were identified as platinum super-sensitive. Patients who had already been diagnosed with primary platinum-resistant disease or as platinum super-responders but had moved on to additional therapy, as well as patients on active anti-cancer therapy or in surveillance, were also included in this study. Patients were excluded if: (1) they were taking antibiotics at the time of sample collection or within 14 days prior to sample collection, or (2) they had active vaginal bleeding or known entero-vaginal fistulae. Samples were also collected from five individuals who were referred for ovarian cancer treatment at the Stephenson Cancer Center but ultimately had benign tumors; these served as a non-chemotherapy exposed control group. Sample collection periods and treatment procedures are outlined in [Fig. S1](#). A brief summary of demographic and medical treatment history for participants in this study ($n = 45$, median age 62.2, age range 33–83) is provided in [Table 1](#). This study was approved by the University of Oklahoma Health Sciences Center Institutional Review Board (February 22nd, 2016,

Table 1 Study group demographics.

	Clinical/lifestyle variable	Study group		
		PFI < 6 months (<i>n</i> = 17)	PFI > 24 months (<i>n</i> = 23)	Benign (<i>n</i> = 5)
	Median age (range)	64.6 (38.5–82.7)	63.6 (45.5–77.9)	57.8 (33.7–79)
Self-reported ethnicity	White (% of study group)	15 (88.2%)	21 (91.3%)	3 (60%)
	African American (%)	1 (5.9%)	1 (4.3%)	0 (0%)
	Native American (%)	1 (5.9%)	1 (4.3%)	2 (40%)
Cytoreductive surgery (CRS)	No surgery (% of study group)	1 (5.9%)	0 (0%)	4 (80%)
	Iterative CRS (%) ^{&}	13 (76.5%)	4 (17.4%)	1 (20%)
	Primary CRS (%) ^{&}	3 (17.6%)	19 (82.6%)	NA
	Median months last platinum cycle (range) ^{&}	7 (1–38)	57 (8–150)	NA
	Expected estrogen positive (%)	4 (23.5%)	9 (39.1%)	1 (20%)
	Take probiotics	4 (23.5%)	4 (17.4%)	1 (20%)
	Vitamin supplement	6 (35.3%)	12 (52.2%)	1 (20%)
	Antibiotics within 6 months	14 (82.4%)	13 (56.5%)	3 (80%)
	Residual disease > 1 cm	6 (35.3%)	3 (13.0%)	NA

Note:

Number of individuals belonging to each study group per clinical/lifestyle variable. The percent of individuals within each study category belonging to each metadata variable are presented in parentheses. Metadata variables that are significantly different between study groups are represented by & and Table S1 presents the *p*-value for each metadata variable.

reference #6458) and all participants gave written informed consent for their participation in the study.

All patients were treated initially with platinum and taxane chemotherapy for a planned six to eight cycles. These regimens included paclitaxel and carboplatin given every 21 days, paclitaxel given weekly with every 21st day carboplatin, or intraperitoneal administration of either cisplatin or carboplatin with intravenous and intraperitoneal paclitaxel. In patients with platinum resistant disease, standard of care options after recurrence included pegylated liposomal doxorubicin (PLD), weekly paclitaxel, gemcitabine, topotecan or bevacizumab given as monotherapy or in combination therapy. Patients were also screened for eligibility for clinical trials. Patients with a PFI > 24 months had not recurred at the time of study participation and were followed every 6 months with surveillance of Ca-125 values and exams. For those who had recurred beyond 24 months, treatment options included several platinum-based doublets including carboplatin and PLD given every 28 days, carboplatin and paclitaxel given every 21 days or carboplatin and gemcitabine given on a day one and day eight or day one and day 15 schedule. Each patient completed a minimum of six cycles of treatment and could undergo more cycles as long as the patient was responding and tolerating therapy.

Sample collection

Samples were collected during standard of care exams in the gynecologic oncology clinic at the Stephenson Cancer Center in Oklahoma City, OK. Catch-All Sample Collection Swabs (Epicentre) were used to collect vaginal and fecal samples. Vaginal swabs were collected from three sites per individual: vaginal introitus (VIT), mid-vagina (MDV), and

posterior fornix (VPF), and then placed into a dry sample collection tube. Fecal samples were collected via a rectal digital exam, after which any stool collected was placed on a Catch-All swab and placed in a dry collection tube. Two swabs were collected from each site (bilaterally from the vaginal sites and sequentially for the rectal samples). Each participant completed a quality-of-life survey regarding their medical treatment history, antibiotic use within the past year, vitamin consumption, socioeconomic status, and other lifestyle metadata (Table S1).

Laboratory methods

DNA was extracted from the left-side vaginal swab and first fecal swab from each patient, using the MoBio PowerSoil DNA Isolation Kit (now Qiagen DNeasy PowerSoil Kit), following manufacturer's protocols with the addition of a ten-minute incubation at 65 °C prior to the initial bead-beating step, as recommended in the Manual of Protocols for the Human Microbiome Project (McInnes & Cutting, 2010). A quantitative PCR (qPCR), using the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and primers targeting the V4 region of the bacterial 16S rRNA gene (Caporaso et al., 2011), was conducted; dilutions of *Escherichia coli* DNA corresponding to known 16S rRNA gene copy numbers were used as quantification standards for the DNA extracts. DNA extracts were amplified in triplicate, using Phusion High-Fidelity DNA polymerase (ThermoFisher Scientific, Waltham, MA, USA) and Illumina-compatible primers 515F and 806R (targeting the V4 region of the 16S rRNA gene) with error-correcting Golay barcodes incorporated into the 806R reverse primer (Caporaso et al., 2011). PCR products were pooled in equimolar concentrations, purified with the MinElute PCR purification kit (Qiagen, Valencia, CA, USA), then size-selected between 300 and 450 basepairs using a PippinPrep, quantified using KAPA Biosystems Illumina library quantification kit, and sequenced across multiple runs of an Illumina MiSeq (500 cycles paired-end sequencing, v2 reagent kit).

Bioinformatic methods

AdapterRemoval (v2) (Schubert, Lindgreen & Orlando, 2016) was used to filter out reads with uncalled bases, reads with Phred quality threshold <30, and reads less than 150 bp in length. Quality filtered paired-end reads were merged using AdapterRemoval (v2) (Schubert, Lindgreen & Orlando, 2016) and then demultiplexed with QIIME (v1.9), followed by removal of chimeric sequences and low-abundance (<5 total sequences) reads (Caporaso et al., 2010). The remaining sequences were used for de novo Operational Taxonomic Unit (OTU) clustering with USEARCH (v10) at 97% sequence similarity (Edgar, 2010). Taxonomy was assigned to each OTU representative using the EzBioCloud 16S rRNA gene database (Yoon et al., 2017). The resulting OTU table was rarefied to 9000 reads and downstream analysis was performed in QIIME (v1.9) (Caporaso et al., 2010). The post-rarefaction sample breakdown was: PFI > 24 ($n = 23$), PFI < 6 ($n = 17$), and benign ($n = 5$). Further details of the bioinformatic methods are given in the Supplemental Material.

Statistical methods

Phylogenetic diversity and weighted/unweighted UniFrac (Lozupone & Knight, 2005) metrics were generated in QIIME (v1.9) with FastTree2 (Price, Dehal & Arkin, 2010). Tests for significance between study groups for alpha and beta diversity were performed using Kruskal-Wallis and PERMANOVA tests, respectively, in R (Team RC, 2013). Vaginal samples were classified into clusters by the dominant bacterial taxon found in each sample, as determined by Ward hierarchical clustering (Ward, 1963), and visualized as a heatmap using the gplots package in R (Warnes et al., 2016). If there were no dominant bacteria, the sample was classified as diverse. Median-unbiased estimated odds ratios were calculated to determine whether study groups had significantly different odds of dominant bacteria; reported odds ratios and 95% confidence intervals were log-transformed. Kruskal-Wallis tests with a Benjamini and Hochberg false-discovery rate adjustment were used to evaluate differential abundance of individual taxa between study groups. Odds ratios were calculated using epitools (Aragon, 2012) in R. Plots were generated using the ggplot2 (Wickham, 2016) and ColorBrewer (Harrower & Brewer, 2003) packages in R.

RESULTS

Vaginal microbiome

Samples from the different vaginal sites (VIT, MDV, VIT) that originated from the same individual showed similar taxonomic beta-diversity profiles (Figs. S2A–S2C). Sequencing failed for at least one of the three vaginal sites of eleven individuals (Supplemental Material), which presented difficulty in analyzing each vaginal site individually as the failed specimens were not limited to only one vaginal site. Due to the similarity in composition between vaginal sites in each individual and the relatively high number of samples which failed sequencing, we concatenated sequencing reads from each individual's three vaginal samples into a single representative vaginal microbiome sample per individual, and then performed downstream analysis with this single representative sample, unless otherwise noted. Combining vaginal sites for each individual allowed us to retain a sample size of 45. Firmicutes was the most dominant phylum in the vaginal microbiome and it was found at over 50% relative abundance in 40% of individuals (Fig. S3A), while Proteobacteria, Bacteroidetes, and Actinobacteria were the next most abundant phyla and found at >50% relative abundance in the vaginal microbiome of 13.3%, 13.3%, and 6.7% of individuals, respectively. At the genus level, *Lactobacillus*, *Prevotella*, *Escherichia*, *Gardnerella*, and *Streptococcus* were the most dominant bacteria and accounted for 57.2% of all reads (Fig. S3B).

Individuals were grouped into the following study groups as outlined in the methods section (Fig. S1): PFI < 6 Months ($n = 17$), PFI > 24 Months ($n = 23$), and benign ($n = 5$). Table 1 presents summary statistics for these study groups. Iterative cytoreductive surgery (iCRS) was more common in PFI < 6 months while primary cytoreductive surgery (pCRS) was more common in PFI > 24 months individuals (log Odds Ratio (OR) = 3.02, 95% CI [1.37–4.68], p -value = 0.0003). As expected, PFI < 6 months




Figure 1 Heatmap of the 25 most abundant genera in the vaginal microbiome. Each column represents a single individual's vaginal microbiome, color coded by study group. Colors of each cell are based on a heatmap, ranging from 0 reads of the bacteria in that individual (white) to 9,000 reads of the bacteria in that individual (red). Samples were rarefied to 9,000 reads, so bright red indicates every read in the sample comes from that bacteria. Samples were clustered together based on similarity of vaginal microbiome using Ward hierarchical clustering. 11 microbiomes were *Lactobacillus*-dominated, six *Escherichia*-dominated, three *Gardnerella*-dominated, nine *Prevotella*, and 16 highly diverse.

Full-size DOI: 10.7717/peerj.11574/fig-1

individuals underwent platinum chemotherapy treatment more recently than PFI > 24 months individuals (p -value = 4.32×10^{-7}) but no other metadata variable was significantly associated with PFI status (Table S2).

Vaginal microbiome communities were clustered into five community-dominance groups using Ward hierarchical clustering: *Lactobacillus* cluster, *Escherichia* cluster, *Gardnerella* cluster, *Prevotella* cluster, and a high diversity cluster (Fig. 1). Results below are presented demonstrating how each vaginal community (excluding *Gardnerella* due to small cluster size) relate to clinical variables, p -values for each vaginal community and clinical variable are given in Table S3.

Dominance groups were evenly distributed between patients with PFI < 6 months, PFI > 24 months, and benign, with the exception of higher-than-expected dominance of




Figure 2 Log-transformed odds ratio vaginal microbiome dominance. Log-transformed odds are represented by the orange circle and the bars represent 95% confidence intervals. *P*-values are given for each odds ratio and a significant result is indicated when the 95% confidence interval is completely greater than 0 or completely less than 0. (A) *Escherichia*-dominance had significantly higher odds of occurring in PFI < 6 months individuals (*p*-value = 0.024). (B) Antibiotics within one month was negatively associated with *Lactobacillus*-dominance, but not significantly (*p*-value = 0.051). There were no differences between medical/health/lifestyle variables in *Prevotella* (C) and highly diverse (D) vaginal microbiomes. *Gardnerella*-dominated communities were not included in this analysis due to small sample size (*n* = 3).

Full-size DOI: 10.7717/peerj.11574/fig-2

Escherichia in patients with PFI < 6 months; five of the six *Escherichia*-dominated vaginal communities identified with hierarchical clustering belonged to patients with PFI < 6 months (Fig. 1). Vaginal microbiomes dominated by *Escherichia* had higher odds of occurring in PFI < 6 months compared to PFI > 24 months (log OR = 2.812, 95% CI [0.267–5.62], *p*-value = 0.024, Fig. 2A). Additionally, one of the patients with PFI < 6 months and one of the patients with benign pathology identified with a ‘diverse’ vaginal microbiome had *Escherichia* at greater than 20% relative abundance, while no other patients with PFI > 24 months had *Escherichia* relative abundance above 5% (Fig. 1).

In total, 35.3% of the patients with PFI < 6 months had *Escherichia* at greater than 20% relative abundance in the vaginal microbiome, compared to 4.34% of PFI > 24 months and only one of five benign individuals. Even though iterative cytoreductive surgery and *Escherichia* are more common in PFI < 6 months individuals, we found no significant relationship between iCRS and *Escherichia* abundance (Table S3, Fig. 2A, p -value = 0.292). Moreover, outside of the relationship between *Escherichia* and platinum resistance, *Escherichia* showed no significant association with any of the other health or lifestyle factors we examined (Table S3, Fig. 2A). Although *Escherichia* is a common lab-grown bacterium and found in feces, our analysis demonstrates *Escherichia* abundance in the vaginal samples is biological and not a technical artifact (Supplemental Material).

Approximately 24% (11 of 45) of patients in this study had *Lactobacillus*-dominated communities, which is significantly lower as compared to studies of similarly aged women without ovarian cancer (p -value = 0.037) (Brotman et al., 2014a; Nené et al., 2019). Other studies have found *Lactobacillus* to be less abundant in Black and Hispanic women (Ravel et al., 2011). and our study consisted of 39 women who self-reported ethnicity as white, two self-reported as Black, and four self-reported as Native American (Table 1). Each of the Black and Native American women had a non-*Lactobacillus* dominated vaginal microbiome (Table S1) but ethnicity was not a statistically significant determinant of *Lactobacillus*-dominance (Fig 2B, log OR = -1.63, 95% CI [-4.62 to 1.30], p -value = 0.27). High microbial cell density, as gauged through qPCR with a standard curve generated from controls with known cell density, was positively correlated with vaginal *Lactobacillus*-dominance, although somewhat weakly ($R^2 = 0.278$, Fig. S4). Consumption of antibiotics within the past month was associated with a lack of *Lactobacillus*-dominance (Fig. 2B); however, this relationship was not significant (log OR = -2.12, 95% CI [-5.54 to 0.84], p -value = 0.0515). Additionally, *Lactobacillus* abundance was uncommon in individuals likely to be estrogen negative (post-menopause and not on hormone replacement therapy) but this result was also not significant (log OR = -1.32, 95% CI [-2.83 to 0.33], p -value = 0.0744). *Lactobacillus*-dominance did not have a strong relationship with any of the other health or lifestyle factors we tested, including PFI length (Table S3, Fig. 2B). Only 20% (1 of 5) of patients with benign pathology had a *Lactobacillus*-dominated microbiome but small sample size prohibits statistical inference.

Previous studies have indicated that different *Lactobacillus* species in the vaginal microbiome may have different roles and differential influence on host biology (Lamont et al., 2011; Arumugam et al., 2011; Schloissnig et al., 2013). While we identified *L. iners*, *L. brevis*, *L. mucosae*, *L. reuteri*, *L. zaeae*, and *L. delbrueckii* in the vaginal microbiome, 99% of the *Lactobacillus* reads in our study were either unclassified at the species level or mapped to *L. iners* (Table S4); ultimately there was not sufficient data to assess the relationship between most of these *Lactobacillus* species and clinical variables. Nevertheless, in individuals with high *Lactobacillus* abundance ($n = 11$), we found *L. iners* at significantly higher abundance in patients with either no gross residual disease or residual disease < 1 cm ($n = 7$), compared to patients with residual disease > 1 cm ($n = 4$, p -value = 0.0359, Fig. 3).




Figure 3 *Lactobacillus iners* dominates in small gross residual disease. *Lactobacillus* reads not assigned to a species were significantly more abundant in individuals with Gross Residual >1 cm (p -value 0.02303). In individuals with *Lactobacillus* dominated vaginal microbiomes ($n = 11$), *L. iners* was at significantly higher relative abundance (p -value = 0.0359) in patients with no gross residual disease or residual disease under 1 cm. [Full-size !\[\]\(1663bb69f307a960345edb0e712f8c02_img.jpg\) DOI: 10.7717/peerj.11574/fig-3](https://doi.org/10.7717/peerj.11574/fig-3)

We did not observe significant associations between either *Prevotella* and clinical variables (Table S3, Fig. 2C) or the high diversity community and clinical variables (Table S3, Fig. 2D). However, *Prevotella* was less common in those with residual disease > 1 cm and those with a history of hormonal disease (Fig. 2C), while a highly diverse vaginal microbiome was more common in women over 60 years old and in patients with a history of hormonal disorders, such as thyroid disease (Fig. 2D); but once again, none of these associations were statistically significant (Table S3, p -value > 0.05).

Gut microbiome

The gut microbiome was colonized by typical members of the gut microbiome at the phylum (Bacteroidetes, Firmicutes, Proteobacteria) and genus (*Bacteroides*, *Akkermansia*, *Faecalibacterium*, *Ruminococcus*, and *Prevotella*) levels (Fig. S5A–S5B). The PFI > 24 months and PFI < 6 months groups were not significantly different with respect to fecal unweighted and weighted UniFrac beta diversity distances as tested through PERMANOVA (Fig. 4, Fig. S6A–S6C); however, similar to the vaginal microbiome samples, there was a small subset of individuals ($n = 9$) with a unique microbiome signature. Patients with PFI < 6 months individuals had higher odds




Figure 4 Unweighted UniFrac distances (PC1 and PC2) of fecal microbiomes from women with ovarian cancer. Each shape represents a single sample and shapes clustering together have similar gut microbiome taxonomic composition. There was no significant difference in overall microbiome community structure between sample groups (PERMANOVA p -value > 0.05); however, there are nine samples (6 PFI < 6 months, 3 PFI > 24 months) that form an outlier group along PC1. These individuals are labelled.

Full-size [DOI: 10.7717/peerj.11574/fig-4](https://doi.org/10.7717/peerj.11574/fig-4)




Figure 5 Phylogenetic diversity in fecal microbiomes. (A) Samples that formed the outlier group in Fig. 4 ($n = 9$) had lower phylogenetic diversity compared to the remainder of the gut microbiome samples (p -value = 0.0001). (B) Patients with PFI < 6 months had lower phylogenetic diversity than benign and platinum-sensitive patients but this was not a significant result (p -value = 0.18).

Full-size [DOI: 10.7717/peerj.11574/fig-5](https://doi.org/10.7717/peerj.11574/fig-5)

(log OR = 1.85, 95% CI [-0.85 to 4.497], p -value = 0.12) of being in this unique/outlier fecal microbiome group. These fecal outliers have significantly lower phylogenetic diversity compared to the other fecal samples (p -value = 0.001, Fig. 5A) and have increased abundance of genera belonging to the order Clostridiales (*Lachnospira* (Kruskal–Wallis

p -value = 0.00039), unidentified Ruminococceae genus (Kruskal–Wallis p -value = 0.001337), and *Subdoligranulum* (Kruskal–Wallis p -value = 0.01121)) (Fig. S7). Of the six platinum-resistant patients in this outlier subset, two also had *Escherichia*-dominated vaginal communities. Eight of the nine patients in this subgroup reported consuming antibiotics within the past 6 months but this was not a significantly greater proportion of individuals with recent antibiotic consumption compared to individuals outside this fecal outlier subgroup (log OR = 0.35, 95% CI [-1.44 to 3.05], p -value = 0.48).

Overall, patients with platinum-resistant disease had lower fecal phylogenetic diversity compared to patients with platinum-sensitive disease, but the difference was not significant (Fig. 5B, p -value = 0.18). Regardless of PFI, patients with ovarian cancer had significantly higher relative abundance of *Prevotella* in the gut microbiome compared to benign individuals (p -value = 0.028, Fig. S8). Outside of the above-mentioned associations, there were no other significant associations between the gut microbiome and platinum sensitivity or other health/lifestyle variables.

DISCUSSION

One of the major findings of this study is the inverse relationship between a *Lactobacillus*-dominant vaginal microbiome and ovarian cancer. In our study, fewer women than expected (24.4%) have *Lactobacillus*-dominated vaginal communities compared to similarly aged, healthy women (47.2%) from other studies (p -value = 0.037) (Brotman et al., 2014a; Nené et al., 2019). *Lactobacillus* dominance is not found in any of the Black ($n = 2$) or Native American ($n = 4$) women in our study but only eleven of the 39 white women have *Lactobacillus*-dominated vaginal microbiomes; therefore, ethnicity was not a driving factor in *Lactobacillus* abundance in this study (p -value = 0.27). These results suggest the possibility that the low abundance of *Lactobacillus* may be indicative of a broader relationship between ovarian cancer and the vaginal microbiome. This finding corroborates a previous study that also observed a reduced frequency of the *Lactobacillus*-dominated vaginal microbiome in women with ovarian cancer, particularly in women under 50 (Nené et al., 2019). A partial explanation may be that *Lactobacillus*-dominance, while typically viewed as a healthy state in the female genital tract, is a non-resilient ecology prone to disruption by variable factors, including changes in glycogen availability (Mirmonsef et al., 2014; Mirmonsef et al., 2015), antibiotic exposure (Melkumyan et al., 2015), and shifts in hormone abundance induced during stress responses (Witkin & Linhares, 2017). While we observed no statistical relationships between *Lactobacillus* dominance and platinum-sensitivity or other lifestyle/medical variables, there was a nearly significant decrease in *Lactobacillus*-dominance associated with taking antibiotics within the past month (p -value = 0.0515), as well as a positive association between *Lactobacillus*-dominance and microbial cell density ($R^2 = 0.278$).

Lactobacillus maintains a low pH in the vaginal environment by producing lactic acid as a byproduct of glycogen metabolism and this low pH inhibits growth of pro-inflammatory bacteria (Champer et al., 2018; Chase et al., 2015; Mirmonsef et al., 2016). Vaginal *Lactobacillus* may protect from gynecological cancers by inhibiting pro-inflammatory bacteria, such as those implicated in pelvic inflammatory disease, and by reducing

inflammatory cytokines IL-1 β and IL-6 (Hemalatha et al., 2012). The low *Lactobacillus* levels we observed may be related to glycogen availability—nearly 75% of women in this study were post-menopause, and vaginally produced glycogen is known to decrease after menopause; likewise, chemotherapy can inhibit ovarian estrogen production and result in lower glycogen levels (Brotman et al., 2014a; Mirmonsef et al., 2016; Bachmann & Nevadunsky, 2000; Muhleisen & Herbst-Kralovetz, 2016). More importantly, many women in this study have had at least one ovary surgically removed during initial cancer treatment. Ovary removal leads to decreased estrogen production and thus, a likely decrease in vaginal glycogen levels; however, more research is needed to fully explain the ovarian-estrogen-glycogen dynamic (Mirmonsef et al., 2014). Glycogen abundance may also help explain the relationship between vaginal microbiome cell density and *Lactobacillus*, as widely available glycogen may encourage a densely colonized *Lactobacillus* vaginal community due to high nutrient availability (Muhleisen & Herbst-Kralovetz, 2016). Hormone replacement therapy (HRT) can be used to replace estrogen production that is stopped after menopause, and four women (two pre-menopause and two post-menopause) were on HRT. Women on HRT or pre-menopause were more likely to have *Lactobacillus*-dominated communities, but this was not significant (p -value = 0.0744). While we did not document glycogen levels in our study, the positive relationship between likely estrogen presence and *Lactobacillus* abundance lends credence to the idea that the low proportion of women with *Lactobacillus* abundance in our study is due to low estrogen, and thus glycogen. The retrospective nature of our study means that we were unable to assess *Lactobacillus* levels in women with ovarian cancer before they progressed to stage III/IV, or prior to chemotherapy. Therefore, we could not investigate anti-gynecological cancer properties of vaginal *Lactobacillus*; nevertheless, by comparing patients in this study to similarly aged women without ovarian cancer, we present further evidence that low *Lactobacillus* levels are more common in women with ovarian cancer (p -value = 0.037).

The presence, and size, of residual disease is strongly correlated with decreased survivability in ovarian cancer (Chang et al., 2013) and therefore our finding that *L. iners* was at significantly higher abundance ($p = 0.0359$) in patients with either no gross residual disease or residual disease < 1 cm after treatment may point to *L. iners* as a potential path toward a biomarker. *L. iners* is a common vaginal bacterium (Ravel et al., 2011; Lewis, Bernstein & Aral, 2017; Younes et al., 2017) but its role in health and disease is sometimes contradictory (Champer et al., 2018); *L. iners* has been found at high relative abundance in low-grade squamous intraepithelial lesions in the cervix but at low abundance in high-grade squamous intraepithelial lesions (Xu et al., 2020). Yet, another study found *L. iners* at high abundance in women with normal cytology when compared to women with squamous intraepithelial lesions (Audirac-Chalifour et al., 2016). Other studies have found *L. iners* to be positively associated with cervical cancer (Oh et al., 2015; Seo et al., 2016) but *L. iners* is also linked to clearance of HPV (Brotman et al., 2014b), which is a causative agent of cervical cancer. Further research is necessary to better understand the role of *L. iners* in gynecological cancers in general, and in the potential inhibition of gross residual disease in ovarian cancer.

Lactobacillus is known to inhibit colonization and growth of *Escherichia* in the vaginal microbiome (Delley et al., 2015; Gupta et al., 1998). The low abundance of *Lactobacillus* found in our study may present ample opportunity for typically low abundance vaginal bacteria, such as *Escherichia*, to thrive and proliferate in the absence of competition. Overgrowth of *Escherichia* only occurred in 17.8% of patients in our study, yet 75% of those patients were in the PFI < 6 months group; this finding was statistically significant (p -value = 0.024). Put another way, 35.3% of patients with PFI < 6 months showed greater than 20% relative abundance of *Escherichia*, as compared to 4.34% of PFI > 24 months and only one of 5 benign cases. The explanation for why *Escherichia* was significantly more common in patients with platinum-resistant tumors is unclear, and because this study was retrospective, we were unable to track *Escherichia* abundance before we knew each patient's platinum-sensitivity. One possible pathway is via interactions between the microbiome, immune system, and how platinum-based chemotherapies induce cancer cell death. Platinum chemotherapies partially rely on ROS produced by host myeloid cells (Iida et al., 2013). Microbes strongly influence immune system function, and hence, alteration in ROS production may be more common in *Escherichia*-dominant vaginal microbiomes, which may render platinum-based chemotherapies less effective, leading to platinum-resistance. Vaginal *Escherichia* may also cause an increased inflammatory response, such as during pelvic inflammatory disease (Heinonen & Miettinen, 1994), and promote cancerous growth, resulting in a shortened PFI. The effect of *Escherichia* on platinum-sensitivity warrants further investigation.

We also observed differences in the gut microbiome of women with platinum-resistant tumors, compared to benign and platinum-sensitive. Similar to the prevalence of *Escherichia*-dominant vaginal microbiomes, 35.3% of patients with PFI < 6 months were fecal beta-diversity outliers compared to the remainder of the fecal samples, while only 13.0% of PFI > 24 and none of the benign cases fell into this cluster (p -value = 0.12). Genera belonging to the Clostridiales order (*Subdoligranulum* (p -value = 0.01121) and *Lachnospira* (p -value = 0.00039)) were at higher abundance in this group of outlier samples. *Subdoligranulum*, has been found at high abundance in the stool of individuals with gastrointestinal neoplasms (Youssef et al., 2018) and has a positive association with blood-based markers of inflammation (De Groot et al., 2017). *Lachnospira* has been found to be positively correlated with a plant-based diet (Vacca et al., 2020) and at high abundance in healthy controls in a study investigating chronic kidney disease (Lun et al., 2019); yet, *Lachnospira* is also found at high abundance in women with metabolic disorder and obesity (Vacca et al., 2020). Additionally, we note lower phylogenetic diversity in the gut microbiome of platinum-resistant tumors compared to both platinum-sensitive and benign tumors (p -value = 0.18). Chemotherapy is a well-documented driver of decreased gut microbiome alpha diversity (Montassier et al., 2015; Hakim et al., 2018; Alexander et al., 2017); however, we did not observe a shift in alpha diversity with time since last cycle of chemotherapy. High gut microbiome alpha diversity is typically associated with improved human health (Menni et al., 2017; Turnbaugh et al., 2009), although recent studies have started to question this paradigm (Reese & Dunn, 2018). Nevertheless, the unique gut microbiome beta diversity profile in a

subset of PFI < 6 months, and the decreased alpha diversity in the full PFI < 6 months population indicates that there may be long term relationship between platinum-resistance and the gut microbiome.

Prevotella is enriched in both the platinum-resistant and platinum-sensitive study groups, compared to the benign group (p -value = 0.028). *Prevotella* is typically only found at high abundance in the gut microbiomes of non-industrial, traditional populations (Ley, 2016) and it is associated with consumption of a plant-rich diet (Ley, 2016). Yet, some strains of *Prevotella* are found in the gut microbiomes of industrial populations and are linked to pro-inflammatory states in the gut microbiome (Larsen, 2017; Scher et al., 2013). Similar to decreased *Lactobacillus* in the vaginal microbiome of patients with ovarian cancer, the relatively high abundance of *Prevotella* in the gut microbiome of women with ovarian cancer indicates a notable shift in microbial composition. Studies with larger control groups are necessary to address this relationship.

CONCLUSIONS

Our results demonstrate an association between the vaginal and gut microbiomes and platinum-sensitivity in women with ovarian cancer. *Escherichia*-dominant vaginal communities are significantly more likely to be present in patients with platinum-resistant tumors but the explanatory mechanism for this relationship is currently unclear. Lab contamination and/or collection methodology does not appear to play a role in vaginal *Escherichia* abundance, which indicates that finding *Escherichia* at high relative abundance in patients with PFI < 6 months is a biological trend.

We also observed shared vaginal and gut microbiome profiles in women with ovarian cancer, with decreased dominance of *Lactobacillus* and increased relative abundance of *Prevotella*, respectively, regardless of platinum-sensitivity. These results suggest shifts in microbiome composition that are related to the ovarian cancer disease state, which may possibly be related to chemotherapy, but the retrospective nature of our study does not allow us to distinguish the exact mechanism of action.

Our results call for deeper investigation into the relationship between the vaginal and gut microbiomes and ovarian cancer. A future avenue for research is a prospective, longitudinal study that tracks how the vaginal and gut microbiomes change throughout the course of ovarian cancer therapy, with an aim to disentangle how *Escherichia*-abundance impacts response to chemotherapy. Similarly, a study tracking *Lactobacillus* abundance in an aged-matched, lifestyle-matched cohort of women with and without ovarian cancer may provide insights into how microbial risk factors impact occurrence and outcomes of ovarian cancer. This work must also investigate why high *L. iners* abundance is found nearly exclusively in cases with < 1 cm or no gross residual disease, while other *Lactobacillus* species are found in cases with > 1 cm residual disease. Finally, ovarian cancer microbiome research also presents an opportunity for microbial metagenomics and metabolomics to provide a fuller picture of the vaginal and gut microbiome ecosystems in health and disease.

ACKNOWLEDGEMENTS

The authors would like to thank Sarah Cooper and Cathy Birdsong for their work in coordinating patient recruitment and monitoring sample collection. The authors would also like to thank all the individuals who participated in this study.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was primarily supported by seed funding from the Stephenson Cancer Center at the University of Oklahoma Health Science Center. National Institutes of Health (NIH R01 GM089886) provided support via shared chemical assay designs and reactions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
Stephenson Cancer Center at the University of Oklahoma Health Science Center.
National Institutes of Health: NIH R01 GM089886.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- David Jacobson performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Kathleen Moore conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Camille Gunderson conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Michelle Rowland performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Rita Austin performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Tanvi Prasad Honap analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Jiawu Xu performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Christina Warinner conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Krithivasan Sankaranarayanan conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

- Cecil M. Lewis Jr conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The University of Oklahoma Health Sciences Center Institutional Review Board approved carry out of this study (Reference #6458).

DNA Deposition

The following information was supplied regarding the deposition of DNA sequences:

16S V4 rRNA sequences are available at NCBI SRA: [SAMN16074939](https://www.ncbi.nlm.nih.gov/sra/SAMN16074939) to [SAMN16075126](https://www.ncbi.nlm.nih.gov/sra/SAMN16075126).

Data Availability

The following information was supplied regarding data availability:

16S V4 rRNA sequences are available at NCBI: project number [PRJNA662091](https://www.ncbi.nlm.nih.gov/submitter/PRJNA662091).
Bioinformatic scripts for processing the 16S rRNA V4 data are available in the [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.11574#supplemental-information>.

REFERENCES

- Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. 2017. Gut microbiota modulation of chemotherapy efficacy and toxicity. *Nature Reviews Gastroenterology & Hepatology* 14(6):356–365 DOI 10.1038/nrgastro.2017.20.
- Aragon T. 2012. *epitools: epidemiology tools R package version 0.5–7*. Berkeley, CA: University of California. Available at <http://CRAN.R-project.org/package=epitools>.
- Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dore J, Meta HITC, Antolin M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariac G, Dervyn R, Foerstner KU, Friss C, Van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Merieux A, Melo Minardi R, M'Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. 2011. Enterotypes of the human gut microbiome. *Nature* 473(7346):174–180 DOI 10.1038/nature09944.
- Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-Barnette J, Cortina-Ceballos B, López-Estrada G, Delgado-Romero K,

- Burguete-García AI, Cantú D. 2016.** Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. *PLOS ONE* **11(4)**:e0153274 DOI [10.1371/journal.pone.0153274](https://doi.org/10.1371/journal.pone.0153274).
- Bachmann GA, Nevadunsky NS. 2000.** Diagnosis and treatment of atrophic vaginitis. *American Family Physician* **61(10)**:3090–3096.
- Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, Van Nagell JR, Seamon LG. 2012.** Ten-year relative survival for epithelial ovarian cancer. *Obstetrics & Gynecology* **120(3)**:612–618 DOI [10.1097/AOG.0b013e318264f794](https://doi.org/10.1097/AOG.0b013e318264f794).
- Bookman MA. 1999.** Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. *Oncologist* **4(2)**:87–94 DOI [10.1634/theoncologist.4-2-87](https://doi.org/10.1634/theoncologist.4-2-87).
- Bossuet-Greif N, Vignard J, Taieb F, Mirey G, Dubois D, Petit C, Oswald E, Nougayrede JP. 2018.** The colibactin genotoxin generates DNA interstrand cross-links in infected cells. *mBio* **9(2)**:e02393-17 DOI [10.1128/mBio.02393-17](https://doi.org/10.1128/mBio.02393-17).
- Brotman RM, Shardell MD, Gajer P, Fadrosch D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE. 2014a.** Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. *Menopause* **21(5)**:450–458 DOI [10.1097/GME.0b013e3182a4690b](https://doi.org/10.1097/GME.0b013e3182a4690b).
- Brotman RM, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, Gravitt PE. 2014b.** Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. *Journal of Infectious Diseases* **210(11)**:1723–1733 DOI [10.1093/infdis/jiu330](https://doi.org/10.1093/infdis/jiu330).
- Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010.** QIIME allows analysis of high-throughput community sequencing data. *Nature Methods* **7(5)**:335–336 DOI [10.1038/nmeth.f.303](https://doi.org/10.1038/nmeth.f.303).
- Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. 2011.** Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proceedings of the National Academy of Sciences of the United States of America* **108(Suppl. 1)**:4516–4522 DOI [10.1073/pnas.1000080107](https://doi.org/10.1073/pnas.1000080107).
- Champer M, Wong AM, Champer J, Brito IL, Messer PW, Hou JY, Wright JD. 2018.** The role of the vaginal microbiome in gynaecological cancer. *BJOG: An International Journal of Obstetrics & Gynaecology* **125(3)**:309–315 DOI [10.1111/1471-0528.14631](https://doi.org/10.1111/1471-0528.14631).
- Chang S-J, Hodeib M, Chang J, Bristow RE. 2013.** Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. *Gynecologic Oncology* **130(3)**:493–498 DOI [10.1016/j.ygyno.2013.05.040](https://doi.org/10.1016/j.ygyno.2013.05.040).
- Chase D, Goulder A, Zenhausern F, Monk B, Herbst-Kralovetz M. 2015.** The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. *Gynecologic Oncology* **138(1)**:190–200 DOI [10.1016/j.ygyno.2015.04.036](https://doi.org/10.1016/j.ygyno.2015.04.036).
- Crusz SM, Balkwill FR. 2015.** Inflammation and cancer: advances and new agents. *Nature Reviews Clinical Oncology* **12(10)**:584–596 DOI [10.1038/nrclinonc.2015.105](https://doi.org/10.1038/nrclinonc.2015.105).
- Dasari S, Tchounwou PB. 2014.** Cisplatin in cancer therapy: molecular mechanisms of action. *European Journal of Pharmacology* **740(Suppl. A)**:364–378 DOI [10.1016/j.ejphar.2014.07.025](https://doi.org/10.1016/j.ejphar.2014.07.025).

- Davis A, Tinker AV, Friedlander M. 2014.** “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? *Gynecologic Oncology* **133**(3):624–631 DOI [10.1016/j.ygyno.2014.02.038](https://doi.org/10.1016/j.ygyno.2014.02.038).
- De Groot PF, Belzer C, Aydin O, Levin E, Levels JH, Aalvink S, Boot F, Holleman F, Van Raalte DH, Scheithauer TP, Simsek S, Schaap FG, Olde Damink SWM, Roep BO, Hoekstra JB, De Vos WM, Nieuwdorp M. 2017.** Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. *PLOS ONE* **12**(12):e0188475 DOI [10.1371/journal.pone.0188475](https://doi.org/10.1371/journal.pone.0188475).
- Delley M, Bruttin A, Richard M, Affolter M, Rezzonico E, Bruck WM. 2015.** *In vitro* activity of commercial probiotic Lactobacillus strains against uropathogenic *Escherichia coli*. *FEMS Microbiology Letters* **362**(13):fnv096 DOI [10.1093/femsle/fnv096](https://doi.org/10.1093/femsle/fnv096).
- Edgar RC. 2010.** Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**(19):2460–2461 DOI [10.1093/bioinformatics/btq461](https://doi.org/10.1093/bioinformatics/btq461).
- Gore M, Fryatt I, Wiltshaw E, Dawson T. 1990.** Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. *Gynecologic Oncology* **36**(2):207–211 DOI [10.1016/0090-8258\(90\)90174-J](https://doi.org/10.1016/0090-8258(90)90174-J).
- Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. 1998.** Inverse association of H₂O₂-producing lactobacilli and vaginal *Escherichia coli* colonization in women with recurrent urinary tract infections. *Journal of Infectious Diseases* **178**(2):446–450 DOI [10.1086/515635](https://doi.org/10.1086/515635).
- Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, Johnson C, Karlsson EA, Chang TC, Jha S, Pui CH, Sun Y, Pounds S, Hayden RT, Tuomanen E, Rosch JW. 2018.** Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic Leukemia. *Clinical Infectious Diseases* **67**(4):541–548 DOI [10.1093/cid/ciy153](https://doi.org/10.1093/cid/ciy153).
- Harrower M, Brewer CA. 2003.** ColorBrewer.org: an online tool for selecting colour schemes for maps. *The Cartographic Journal* **40**(1):27–37 DOI [10.1179/000870403235002042](https://doi.org/10.1179/000870403235002042).
- Heinonen PK, Miettinen A. 1994.** Laparoscopic study on the microbiology and severity of acute pelvic inflammatory disease. *European Journal of Obstetrics & Gynecology and Reproductive Biology* **57**(2):85–89 DOI [10.1016/0028-2243\(94\)90048-5](https://doi.org/10.1016/0028-2243(94)90048-5).
- Hemalatha R, Mastromarino P, Ramalaxmi BA, Balakrishna NV, Sesikeran B. 2012.** Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study. *European Journal of Clinical Microbiology & Infectious Diseases* **31**(11):3097–3105 DOI [10.1007/s10096-012-1671-1](https://doi.org/10.1007/s10096-012-1671-1).
- Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank KM, Belkaid Y, Trinchieri G, Goldszmid RS. 2013.** Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science* **342**(6161):967–970 DOI [10.1126/science.1240527](https://doi.org/10.1126/science.1240527).
- Jacobs IJ, Menon U. 2004.** Progress and challenges in screening for early detection of ovarian cancer. *Molecular & Cellular Proteomics* **3**(4):355–366 DOI [10.1074/mcp.R400006-MCP200](https://doi.org/10.1074/mcp.R400006-MCP200).
- Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, Romero R. 2011.** The vaginal microbiome: new information about genital tract flora using molecular based techniques. *BJOG: An International Journal of Obstetrics & Gynaecology* **118**(5):533–549 DOI [10.1111/j.1471-0528.2010.02840.x](https://doi.org/10.1111/j.1471-0528.2010.02840.x).
- Larsen JM. 2017.** The immune response to *Prevotella* bacteria in chronic inflammatory disease. *Immunology* **151**(4):363–374 DOI [10.1111/imm.12760](https://doi.org/10.1111/imm.12760).

- Lewis FM, Bernstein KT, Aral SO. 2017. Vaginal microbiome and its relationship to behavior, sexual health, and sexually transmitted diseases. *Obstetrics & Gynecology* **129**(4):643–654 DOI [10.1097/AOG.0000000000001932](https://doi.org/10.1097/AOG.0000000000001932).
- Ley RE. 2016. Gut microbiota in 2015—prevotella in the gut: choose carefully. *Nature Reviews Gastroenterology & Hepatology* **13**(2):69–70 DOI [10.1038/nrgastro.2016.4](https://doi.org/10.1038/nrgastro.2016.4).
- Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, Wu SC, Lai YL. 2011. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. *Lancet Oncology* **12**(9):900–904 DOI [10.1016/S1470-2045\(11\)70165-6](https://doi.org/10.1016/S1470-2045(11)70165-6).
- Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial communities. *Applied and Environmental Microbiology* **71**(12):8228–8235 DOI [10.1128/AEM.71.12.8228-8235.2005](https://doi.org/10.1128/AEM.71.12.8228-8235.2005).
- Lun H, Yang W, Zhao S, Jiang M, Xu M, Liu F, Wang Y. 2019. Altered gut microbiota and microbial biomarkers associated with chronic kidney disease. *MicrobiologyOpen* **8**(4):e00678 DOI [10.1002/mbo3.678](https://doi.org/10.1002/mbo3.678).
- Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr. 1991. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. *Journal of Clinical Oncology* **9**(3):389–393 DOI [10.1200/JCO.1991.9.3.389](https://doi.org/10.1200/JCO.1991.9.3.389).
- McInnes P, Cutting M. 2010. Manual of procedures for human microbiome project, core microbiome sampling, protocol A—HMP protocol #07-001. Available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000228.v3.p1&phd=3190.
- Melkumyan A, Pripitnevich T, Ankirskaya A, Murav'eva V, Lubasovskaya L. 2015. Effects of antibiotic treatment on the lactobacillus composition of vaginal microbiota. *Bulletin of Experimental Biology and Medicine* **158**(6):766–768 DOI [10.1007/s10517-015-2857-1](https://doi.org/10.1007/s10517-015-2857-1).
- Menni C, Jackson MA, Pallister T, Steves CJ, Spector TD, Valdes AM. 2017. Gut microbiome diversity and high-fibre intake are related to lower long-term weight gain. *International Journal of Obesity* **41**(7):1099–1105 DOI [10.1038/ijo.2017.66](https://doi.org/10.1038/ijo.2017.66).
- Mirmonsef P, Hottot AL, Gilbert D, Burgad D, Landay A, Weber KM, Cohen M, Ravel J, Spear GT. 2014. Free glycogen in vaginal fluids is associated with Lactobacillus colonization and low vaginal pH. *PLOS ONE* **9**(7):e102467 DOI [10.1371/journal.pone.0102467](https://doi.org/10.1371/journal.pone.0102467).
- Mirmonsef P, Hottot AL, Gilbert D, Gioia CJ, Maric D, Hope TJ, Landay AL, Spear GT. 2016. Glycogen levels in undiluted genital fluid and their relationship to vaginal pH, estrogen, and progesterone. *PLOS ONE* **11**(4):e0153553 DOI [10.1371/journal.pone.0153553](https://doi.org/10.1371/journal.pone.0153553).
- Mirmonsef P, Modur S, Burgad D, Gilbert D, Golub ET, French AL, McCotter K, Landay AL, Spear GT. 2015. An exploratory comparison of vaginal glycogen and Lactobacillus levels in pre- and post-menopausal women. *Menopause* **22**(7):702–709 DOI [10.1097/GME.0000000000000397](https://doi.org/10.1097/GME.0000000000000397).
- Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, Moreau P, Potel G, De La Cochetiere MF, Batard E, Knights D. 2015. Chemotherapy-driven dysbiosis in the intestinal microbiome. *Alimentary Pharmacology & Therapeutics* **42**(5):515–528 DOI [10.1111/apt.13302](https://doi.org/10.1111/apt.13302).
- Muhleisen AL, Herbst-Kralovetz MM. 2016. Menopause and the vaginal microbiome. *Maturitas* **91**(1):42–50 DOI [10.1016/j.maturitas.2016.05.015](https://doi.org/10.1016/j.maturitas.2016.05.015).
- Muls A, Andreyev J, Lalondrelle S, Taylor A, Norton C, Hart A. 2017. Systematic review: the impact of cancer treatment on the gut and vaginal microbiome in women with a Gynecological Malignancy. *International Journal of Gynecologic Cancer* **27**(7):1550–1559 DOI [10.1097/IGC.0000000000000999](https://doi.org/10.1097/IGC.0000000000000999).

- Nené NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, Knapp S, Ryan A, Ghazali S, Timms JF. 2019. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. *The Lancet Oncology* 20(8):1171–1182 DOI 10.1016/S1470-2045(19)30340-7.
- Oh HY, Kim BS, Seo SS, Kong JS, Lee JK, Park SY, Hong KM, Kim HK, Kim MK. 2015. The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. *Clinical Microbiology and Infection* 21(7):674.e1–674.e9 DOI 10.1016/j.cmi.2015.02.026.
- Ozben T. 2007. Oxidative stress and apoptosis: impact on cancer therapy. *Journal of Pharmaceutical Sciences* 96(9):2181–2196 DOI 10.1002/jps.20874.
- Perez-Chanona E, Trinchieri G. 2016. The role of microbiota in cancer therapy. *Current Opinion in Immunology* 39(Suppl. 3):75–81 DOI 10.1016/j.coi.2016.01.003.
- Pfisterer J, Ledermann JA. 2006. Management of platinum-sensitive recurrent ovarian cancer. *Seminars in Oncology* 33:12–16.
- Price MN, Dehal PS, Arkin AP. 2010. FastTree 2—approximately maximum-likelihood trees for large alignments. *PLOS ONE* 5(3):e9490 DOI 10.1371/journal.pone.0009490.
- Raja FA, Chopra N, Ledermann JA. 2012. Optimal first-line treatment in ovarian cancer. *Annals of Oncology* 23(Suppl. 10):x118–x127 DOI 10.1093/annonc/mds315.
- Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. 2011. Vaginal microbiome of reproductive-age women. *Proceedings of the National Academy of Sciences* 108(Suppl. 1):4680–4687 DOI 10.1073/pnas.1002611107.
- Reese AT, Dunn RR. 2018. Drivers of microbiome biodiversity: a review of general rules, feces, and ignorance. *mBio* 9(4):e01294-18 DOI 10.1128/mBio.01294-18.
- Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR. 2013. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *elife* 2:e01202 DOI 10.7554/eLife.01202.
- Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, Zhu A, Waller A, Mende DR, Kultima JR, Martin J, Kota K, Sunyaev SR, Weinstock GM, Bork P. 2013. Genomic variation landscape of the human gut microbiome. *Nature* 493(7430):45–50 DOI 10.1038/nature11711.
- Schubert M, Lindgreen S, Orlando L. 2016. AdapterRemoval v2: rapid adapter trimming, identification, and read merging. *BMC Research Notes* 9(1):88 DOI 10.1186/s13104-016-1900-2.
- Schwabe RF, Jobin C. 2013. The microbiome and cancer. *Nature Reviews Cancer* 13(11):800–812 DOI 10.1038/nrc3610.
- Seo SS, Oh HY, Lee JK, Kong JS, Lee DO, Kim MK. 2016. Combined effect of diet and cervical microbiome on the risk of cervical intraepithelial neoplasia. *Clinical Nutrition* 35(6):1434–1441 DOI 10.1016/j.clnu.2016.03.019.
- Sharma H, Tal R, Clark NA, Segars JH. 2014. Microbiota and pelvic inflammatory disease. *Seminars in Reproductive Medicine* 32(1):43–49 DOI 10.1055/s-0033-1361822.
- Shi N, Li N, Duan X, Niu H. 2017. Interaction between the gut microbiome and mucosal immune system. *Military Medical Research* 4(1):1–7 DOI 10.1186/s40779-017-0122-9.
- Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians* 69(1):7–34 DOI 10.3322/caac.21551.
- Team RC. 2013. *R: a language and environment for statistical computing*. Vienna: The R Foundation for Statistical Computing. Available at <http://www.R-project.org/>.

- Thaiss CA, Zmora N, Levy M, Elinav E. 2016. The microbiome and innate immunity. *Nature* 535(7610):65–74 DOI 10.1038/nature18847.
- Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. 2018. Ovarian cancer statistics, 2018. *CA: A Cancer Journal for Clinicians* 68(4):284–296 DOI 10.3322/caac.21456.
- Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. 2009. A core gut microbiome in obese and lean twins. *Nature* 457(7228):480–484 DOI 10.1038/nature07540.
- Ushijima K. 2010. Treatment for recurrent ovarian cancer—at first relapse. *Journal of Oncology* 2010:497429 DOI 10.1155/2010/497429.
- Vacca M, Celano G, Calabrese FM, Portincasa P, Gobetti M, De Angelis M. 2020. The controversial role of human gut Lachnospiraceae. *Microorganisms* 8(4):573 DOI 10.3390/microorganisms8040573.
- Ward JH Jr. 1963. Hierarchical grouping to optimize an objective function. *Journal of the American Statistical Association* 58(301):236–244 DOI 10.1080/01621459.1963.10500845.
- Warnes MGR, Bolker B, Bonebakker L, Gentleman R, Huber W. 2016. Package ‘gplots’: various R programming tools for plotting data. Available at <https://rdrr.io/cran/gplots/>.
- Wickham H. 2016. *ggplot2: elegant graphics for data analysis*. Berlin: Springer.
- Witkin SS, Linhares IM. 2017. Why do lactobacilli dominate the human vaginal microbiota? *BJOG: An International Journal of Obstetrics & Gynaecology* 124(4):606–611 DOI 10.1111/1471-0528.14390.
- Xu J, Peng JJ, Yang W, Fu K, Zhang Y. 2020. Vaginal microbiomes and ovarian cancer: a review. *American Journal of Cancer Research* 10(3):743–756.
- Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, Chun J. 2017. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. *International Journal of Systematic and Evolutionary Microbiology* 67(5):1613–1617 DOI 10.1099/ijsem.0.001755.
- Younes JA, Lievens E, Hummelen R, Van der Westen R, Reid G, Petrova MI. 2017. Women and their microbes: the unexpected friendship. *Trends in Microbiology* 26(1):16–32 DOI 10.1016/j.tim.2017.07.008.
- Youssef O, Lahti L, Kokkola A, Karla T, Tikkanen M, Ehsan H, Carpelan-Holmstrom M, Koskensalo S, Bohling T, Rautelin H, Puolakkainen P, Knuutila S, Sarhadi V. 2018. Stool microbiota composition differs in patients with stomach, colon, and rectal neoplasms. *Digestive Diseases and Sciences* 63(11):2950–2958 DOI 10.1007/s10620-018-5190-5.
- Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD. 2013. The gut microbiome modulates colon tumorigenesis. *mBio* 4(6):e00692-13 DOI 10.1128/mBio.00692-13.
- Zackular JP, Rogers MA, Ruffin MT, Schloss PD. 2014. The human gut microbiome as a screening tool for colorectal cancer. *Cancer Prevention Research* 7(11):1112–1121 DOI 10.1158/1940-6207.CAPR-14-0129.